| URL | https://www.contractpharma.com/contents/view_break |
| Source | Contract Pharma |
| Date Published | 03/03/2023 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Actylis |
| Parent company | Actylis |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2023 |
| City reshored to: | Eugene |
| State(s) reshored to: | OR |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma |
| What domestic positive factors made reshoring more attractive? | Customization/Flexibility, Eco-system synergies, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market |